Compliance to levothyroxine treatment of the patients with hypothyroidism during SARS-CoV-2 pandemic era

Basit Öğe Kaydı
dc.authorscopusid57208133158
dc.authorscopusid58491811000
dc.authorscopusid57221930063
dc.authorscopusid55976415400
dc.authorscopusid57208134255
dc.authorscopusid57221775235
dc.authorscopusid57221783876
dc.contributor.authorBilgin, Satilmis
dc.contributor.authorMeryem, Burcin
dc.contributor.authorTel, Atak
dc.contributor.authorDuman, Tuba Taslamacioglu
dc.contributor.authorKurtkulagi, Ozge
dc.contributor.authorKahveci, Gizem Bakir
dc.contributor.authorSagdic, Tugrul
dc.date.accessioned2024-09-25T19:45:06Z
dc.date.available2024-09-25T19:45:06Z
dc.date.issued2021
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractBackground. Hypothyroidism requires treatment with levothyroxine (L-T4) to keep patients euthyroid. The rate of hospital admissions for chronic conditions decreased during COVID-19 era. We aimed to observe whether hospital admissions of the patients with hypothyroidism decreased during COVID-19 compared to the same time period in 2019. We also aimed to find out the rate of treatment compliance in subjects with hypothyroidism during pandemic era. Materials and methods. This cross-sectional study was performed on patients who applied to Internal Medicine Department of Abant Izzet Baysal University Hospital, and who received L-T4 replacement therapy due to hypothyroidism. 108 hypothyroidism patients were included in the study with their consent forms. The patients were divided into 2 groups according to the treatment compliance; either as compliant or incompliant patients. Results. The last TSH level of compliant group was significantly lower than incompliant group (p < 0.001). The last fT4 level of the compliant group was significantly higher than that of the incompliant group (p = 0.04). The median of the LT-4 treatment used irregularly was 35 (10–90) days in incompliant group and was 0 (0–0) days in compliant group (p < 0.001). The number of irregularly L-T4 used days was significantly positively correlated with last TSH value (r = 0.564, p < 0.001), and negatively correlated with last FT4 value (r = –0.492, p < 0.001). Mean corpuscular volume (MCV) of the compliant and incompliant groups were 85 (69.1–97.5) fL and 89 (66–96.6) fL, respectively (p = 0.03). Retrospective nature and relatively small study population are two main limitations of our study. Conclusions. Compliance to treatment is very important to achieve euthyroid hormone levels in patients with hypothyroidism during COVID-19 pandemic. Elevated MCV levels could predict incompliance to treatment in hypothyroidism. © 2021. The Authors.en_US
dc.identifier.doi10.22141/2224-0721.17.2.2021.230563
dc.identifier.endpage107en_US
dc.identifier.issn2224-0721
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85121854192en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage103en_US
dc.identifier.urihttps://doi.org/10.22141/2224-0721.17.2.2021.230563
dc.identifier.urihttps://hdl.handle.net/20.500.12491/12862
dc.identifier.volume17en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherZaslavsky Publishing Houseen_US
dc.relation.ispartofMiznarodnij Endokrinologicnij Zurnalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzYK_20240925en_US
dc.subjectcomplianceen_US
dc.subjecthypothyroidismen_US
dc.subjectlevothyroxineen_US
dc.subjectthyroid stimulation hormoneen_US
dc.titleCompliance to levothyroxine treatment of the patients with hypothyroidism during SARS-CoV-2 pandemic eraen_US
dc.title.alternative????????? ?? ????????? ?????????????? ?????? ?? ?????????? ??? ??? ??????????? ??? SARS-CoV-2]en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu